Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Traffic & App Usage Insights

Discover domain traffic and app usage trends for companies and their competitors.

PSTX

Poseida Therapeutics Inc

Oct 31 • 04:00PM ET

2.37

Dollar change -0.01
Percentage change -0.42	%

Healthcare • Biotechnology • USA • NASD

Peers: CRSP BMRN NTLA BLUE EDIT RGNX QURE SGMO VYGR ADVM

| Held by: VTI IWM VXF IWN VTWO SCHA IWO IWC GNOM XDNA

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-1.19	Insider Own	33.00%	Shs Outstand	95.64M	Perf Week	-2.07%
Market Cap	230.21M	Forward P/E	-	EPS next Y	-1.84	Insider Trans	0.00%	Shs Float	65.08M	Perf Month	-10.23%
Income	-112.77M	PEG	-	EPS next Q	-0.42	Inst Own	50.06%	Short Float	7.40%	Perf Quarter	-23.55%
Sales	88.46M	P/S	2.60	EPS this Y	-3.10%	Inst Trans	0.94%	Short Ratio	10.93	Perf Half Y	-15.05%
Book/sh	0.63	P/B	3.78	EPS next Y	-30.09%	ROA	-38.89%	Short Interest	4.81M	Perf Year	17.33%
Cash/sh	2.45	P/C	0.97	EPS next 5Y	2.70%	ROE	-115.00%	52W Range	1.87 - 4.27	Perf YTD	-29.46%
Dividend Est.	-	P/FCF	1096.23	EPS past 5Y	-12.83%	ROI	-81.46%	52W High	-44.50%	Beta	0.51
Dividend TTM	-	Quick Ratio	2.48	Sales past 5Y	53.46%	Gross Margin	93.66%	52W Low	26.74%	ATR (14)	0.13
Dividend Ex-Date	-	Current Ratio	2.48	EPS Y/Y TTM	-413.27%	Oper. Margin	-133.92%	RSI (14)	34.97	Volatility	3.73% 4.21%
Employees	330	Debt/Eq	1.38	Sales Y/Y TTM	-43.55%	Profit Margin	-127.48%	Recom	1.00	Target Price	14.00
Option/Short	Yes / Yes	LT Debt/Eq	1.28	EPS Q/Q	-2.28%	Payout	-	Rel Volume	0.61	Prev Close	2.38
Sales Surprise	68.65%	EPS Surprise	21.32%	Sales Q/Q	29.78%	Earnings	Aug 05 AMC	Avg Volume	440.30K	Price	2.37
SMA20	-5.12%	SMA50	-14.36%	SMA200	-20.62%	Trades		Volume	266,784	Change	-0.42%

Date	Action	Analyst	Rating Change	Price Target Change
Jan-04-23	Initiated	H.C. Wainwright	Buy	$15
Jan-07-22	Initiated	Cantor Fitzgerald	Overweight	$24
May-18-21	Initiated	BTIG Research	Buy	$40
Aug-04-20	Initiated	William Blair	Outperform
Aug-04-20	Initiated	Piper Sandler	Overweight	$30
Aug-04-20	Initiated	BofA Securities	Buy	$20

Oct-24-24 08:00AM	Poseida Therapeutics to Present New Preclinical Data Supporting Non-Viral Gene Editing with P-KLKB1-101 for the Treatment of Hereditary Angioedema (PR Newswire)
Oct-17-24 08:00AM	Poseida Therapeutics Announces Nomination of New CAR-T Development Candidate Under Collaboration with Roche (PR Newswire)
Oct-15-24 08:05AM	MaxCyte Appoints Cynthia Collins to its Board of Directors (GlobeNewswire)
Oct-03-24 04:30PM	Poseida Therapeutics Named to Newsweek's List of the Top 200 America's Most Loved Workplaces for 2024 (PR Newswire)
Sep-27-24 04:30PM	Poseida Therapeutics Reports Positive Interim Phase 1 Results for Allogeneic CAR-T Therapy P-BCMA-ALLO1 with High Overall Response Rates in Heavily Pretreated Relapsed/Refractory Multiple Myeloma Patients (PR Newswire)
04:12AM	Loading…
Sep-17-24 04:12AM	FDA grants RMAT to Poseidas CAR-T cell therapy P-BCMA-ALLO1 (Pharmaceutical Technology) +12.67%
Sep-16-24 08:00AM	Poseida Therapeutics Receives Regenerative Medicine Advanced Therapy (RMAT) Designation from FDA for P-BCMA-ALLO1 to Treat Relapsed/Refractory Multiple Myeloma (PR Newswire)
Sep-05-24 09:00AM	Poseida Therapeutics to Present New Clinical Data from Phase 1 Study of Allogeneic CAR-T P-BCMA-ALLO1 in Patients with Relapsed/Refractory Multiple Myeloma at 21st International Myeloma Society Annual Meeting (PR Newswire)
Sep-04-24 04:05PM	Poseida Therapeutics Presents New Case Study Demonstrating Reactivation of CAR-T Therapy with a T-Cell Engager in a Patient with Relapsed Multiple Myeloma (PR Newswire)
Aug-29-24 04:05PM	Poseida Therapeutics to Present at Upcoming Investor Conferences (PR Newswire)
Aug-05-24 09:55PM	PSTX Stock Earnings: Poseida Therapeutics Beats EPS, Beats Revenue for Q2 2024 (InvestorPlace)
05:55PM	Poseida Therapeutics, Inc. (PSTX) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
04:05PM	Poseida Therapeutics Provides Updates and Financial Results for the Second Quarter of 2024 (PR Newswire)
Jul-19-24 12:00PM	Are You Looking for a Top Momentum Pick? Why Poseida Therapeutics, Inc. (PSTX) is a Great Choice (Zacks) -5.26%
Jul-01-24 04:05PM	Poseida Therapeutics Announces Participation in Stifel's 2024 Virtual Cell Therapy Forum (PR Newswire)
04:05PM	Loading…
Jun-03-24 04:05PM	Poseida Therapeutics Announces Virtual 2024 Annual Meeting of Stockholders (PR Newswire) -13.40%
May-14-24 09:53PM	PSTX Stock Earnings: Poseida Therapeutics Beats EPS, Beats Revenue for Q1 2024 (InvestorPlace) +18.49%
05:08PM	Poseida Therapeutics Q1 Net Loss Narrows, Revenue Rises (MT Newswires)
04:05PM	Poseida Therapeutics Provides Updates and Financial Results for the First Quarter of 2024 (PR Newswire)
May-09-24 09:00AM	Poseida Highlights Strong Progress on Its Genetic Medicine Programs at the American Society for Gene and Cell Therapy 27th Annual Meeting (PR Newswire)
May-02-24 06:22AM	Xyphos and Poseida to develop allogeneic cell therapies for cancer (Pharmaceutical Technology)
06:04AM	Poseida Therapeutics to Receive Up to $600 Million in Cancer Gene Therapy Research, Development Deal With Xyphos (MT Newswires)
May-01-24 09:30PM	Astellas and Poseida Therapeutics Enter Into Research Collaboration and License Agreement to Develop Novel Allogeneic Cell Therapies in Oncology (PR Newswire) +14.46%
05:42AM	Astellas adds to off-the-shelf cell therapy capabilities with Poseida deal (BioPharma Dive)
Apr-18-24 08:00AM	Poseida Therapeutics Announces Strong Lineup of Presentations at the American Society of Gene and Cell Therapy 27th Annual Meeting (PR Newswire)
Apr-17-24 09:00AM	Poseida Therapeutics Hosts Gene Therapy R&D Day Highlighting New Scientific Advancements and Pipeline Focus (PR Newswire)
Apr-08-24 12:00PM	Poseida Therapeutics Presents New Phase 1 Data at AACR 2024 Supporting Potential of P-BCMA-ALLO1 Allogeneic CAR-T Therapy to Benefit Broad Range of Patients with Multiple Myeloma (PR Newswire)
Apr-01-24 04:05PM	Poseida Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (PR Newswire) -6.45%
Mar-25-24 04:05PM	Poseida Therapeutics Appoints Syed Rizvi, M.D., as Chief Medical Officer (PR Newswire) -7.57%
Mar-19-24 04:05PM	Poseida Therapeutics to Present at H.C. Wainwright 2nd Annual Cell Therapy Virtual Conference (PR Newswire)
04:05PM	Loading…
Mar-13-24 04:05PM	Poseida Therapeutics Announces FDA Orphan Drug Designation Granted to P-BCMA-ALLO1 for the Treatment of Multiple Myeloma (PR Newswire) +7.57%
Mar-07-24 10:53PM	PSTX Stock Earnings: Poseida Therapeutics Beats EPS, Beats Revenue for Q4 2023 (InvestorPlace) +18.66%
10:45PM	Poseida Therapeutics Inc (PSTX) Reports Fourth Quarter and Full Year 2023 Financial Results (GuruFocus.com)
06:55PM	Poseida Therapeutics, Inc. (PSTX) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
04:07PM	Poseida Therapeutics Provides Updates and Financial Results for the Fourth Quarter and Full Year 2023 (PR Newswire)
Mar-04-24 04:05PM	Poseida Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (PR Newswire) -10.77% -5.56%
Jan-04-24 08:00AM	Poseida Therapeutics Highlights Recent Progress, Strategic Priorities and Anticipated 2024 Key Milestones (PR Newswire)
Dec-10-23 12:00PM	Poseida Therapeutics Presents Positive Early Results from its Phase 1 Trial of Allogeneic CAR-T P-BCMA-ALLO1 in Relapsed-Refractory Multiple Myeloma at the 65th American Society of Hematology (ASH) Annual Meeting (PR Newswire)
Nov-17-23 01:08PM	Biotech Breakthroughs: 3 Revolutionary Stocks Redefining Healthcare (InvestorPlace) +5.58%
Nov-09-23 04:05PM	Poseida Therapeutics Provides Updates and Financial Results for the Third Quarter of 2023 (PR Newswire)
Nov-07-23 08:00AM	Poseida Therapeutics to Present at Two Upcoming Investor Conferences (PR Newswire)
Nov-02-23 10:00AM	Poseida Therapeutics, Inc. (PSTX) Expected to Beat Earnings Estimates: Can the Stock Move Higher? (Zacks) +5.31%
09:01AM	Poseida Therapeutics to Present at the 65th ASH Annual Meeting and Exposition (PR Newswire)
Oct-16-23 12:00PM	All You Need to Know About Poseida Therapeutics, Inc. (PSTX) Rating Upgrade to Buy (Zacks) +6.41%
Oct-09-23 04:30PM	Poseida Therapeutics Announces Leadership Transition (PR Newswire)
Oct-03-23 05:00PM	Biotechnology Breakthroughs: 3 Biotech Stocks That Could Make Early Investors Rich (InvestorPlace)
Sep-05-23 08:00AM	Poseida Therapeutics to Present at Two Upcoming Investor Conferences (PR Newswire)
Aug-10-23 06:02AM	News Flash: Analysts Just Made An Upgrade To Their Poseida Therapeutics, Inc. (NASDAQ:PSTX) Forecasts (Simply Wall St.)
Aug-08-23 05:40PM	Poseida Therapeutics, Inc. (PSTX) Reports Q2 Loss, Tops Revenue Estimates (Zacks) +37.88%
04:05PM	Poseida Therapeutics Provides Financial Results for the Second Quarter of 2023 (PR Newswire)
Aug-07-23 09:01AM	Poseida Therapeutics Announces Strategic Investment by Astellas and Provides Business Update (PR Newswire) +21.47%
09:00AM	Astellas and Poseida Therapeutics Announce Strategic Investment to Support Poseida's Commitment to Redefining Cancer Cell Therapy (PR Newswire)
Jul-31-23 08:23AM	The past three years for Poseida Therapeutics (NASDAQ:PSTX) investors has not been profitable (Simply Wall St.)
Jul-05-23 08:00AM	Poseida Therapeutics Announces FDA Clearance of Investigational New Drug Application for P-CD19CD20-ALLO1, an Allogeneic Dual CAR-T Cell Therapy for B-Cell Malignancies (PR Newswire)
Jun-26-23 08:00AM	Poseida Therapeutics to Join Russell 3000® and Russell 2000® Indexes (PR Newswire) -11.06%
Jun-01-23 08:00AM	Poseida Therapeutics Announces Virtual 2023 Annual Meeting of Stockholders (PR Newswire)
May-23-23 08:00AM	Poseida Therapeutics to Present at Stifel 2023 Tailoring Genes: Genetic Medicines Day (PR Newswire)
May-22-23 08:00AM	Poseida Therapeutics to Present at 31st Congress of the International Society on Thrombosis and Haemostasis (PR Newswire) +9.30%
May-18-23 08:00AM	Poseida Therapeutics Presents Encouraging Preclinical Data Across its Gene Therapy Programs at the American Society for Gene and Cell Therapy 2023 Annual Meeting (PR Newswire) -6.67%
May-11-23 06:11AM	Poseida Therapeutics First Quarter 2023 Earnings: Revenues Beat Expectations, EPS Lags (Simply Wall St.) -9.00%
May-10-23 12:00PM	What Makes Poseida Therapeutics, Inc. (PSTX) a New Buy Stock (Zacks)
May-09-23 07:05PM	Poseida Therapeutics, Inc. (PSTX) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
04:05PM	Poseida Therapeutics Provides Updates and Financial Results for the First Quarter of 2023 (PR Newswire)
May-02-23 04:30PM	Poseida Therapeutics Announces Multiple Presentations at the American Society of Gene and Cell Therapy 26th Annual Meeting (PR Newswire)
May-01-23 08:00AM	Poseida Therapeutics to Present at BofA Securities 2023 Health Care Conference (PR Newswire)
Apr-17-23 06:48AM	Benign Growth For Poseida Therapeutics, Inc. (NASDAQ:PSTX) Underpins Stock's 44% Plummet (Simply Wall St.)
Apr-13-23 08:00AM	Poseida Therapeutics Appoints Rafael G. Amado, M.D., to Board of Directors (PR Newswire)
Apr-11-23 04:05PM	Poseida Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (PR Newswire) -5.73%
08:00AM	Poseida Therapeutics Appoints Kristin Yarema, Ph.D., as President, Cell Therapy (PR Newswire)
Apr-03-23 07:09AM	With 46% stake, Poseida Therapeutics, Inc. (NASDAQ:PSTX) seems to have captured institutional investors' interest (Simply Wall St.)
Mar-09-23 06:05PM	Poseida Therapeutics, Inc. (PSTX) Reports Q4 Loss, Misses Revenue Estimates (Zacks) -7.17% -18.81%
04:05PM	Poseida Therapeutics Provides Updates and Financial Results for the Fourth Quarter and Full Year 2022 (PR Newswire)
Mar-01-23 08:00AM	Poseida Therapeutics Appoints Five New Members to Its Gene Therapy Scientific Advisory Board (PR Newswire) -5.98%
Feb-22-23 08:00AM	Poseida Therapeutics Hosts Third Annual Virtual R&D Day Highlighting Novel Pipeline Assets and Latest Technology Innovations (PR Newswire)
Feb-21-23 06:50AM	Poseida Therapeutics (NASDAQ:PSTX) shareholders are still up 91% over 1 year despite pulling back 10.0% in the past week (Simply Wall St.)
Feb-15-23 08:50AM	Here's What Could Help Poseida Therapeutics, Inc. (PSTX) Maintain Its Recent Price Strength (Zacks) -8.05%
Feb-14-23 08:00AM	Poseida Therapeutics to Present at H.C. Wainwright Cell Therapy Virtual Conference (PR Newswire)
Feb-08-23 08:00AM	Poseida Therapeutics to Host Third Annual Virtual R&D Day on February 22, 2023 (PR Newswire)
Jan-31-23 04:05PM	Poseida Therapeutics Announces Board Change (PR Newswire)
Jan-27-23 08:50AM	Poseida Therapeutics, Inc. (PSTX) is on the Move, Here's Why the Trend Could be Sustainable (Zacks)
Jan-25-23 11:16AM	How to Nab a 78% Gain in 8 Weeks (InvestorPlace)
Jan-10-23 08:50AM	Recent Price Trend in Poseida Therapeutics, Inc. (PSTX) is Your Friend, Here's Why (Zacks)
Jan-04-23 02:51PM	Poseida Therapeutics Ushers New Era For Gene Therapies, Analyst Initiating Coverage Says (Benzinga) +14.51%
Dec-15-22 08:50AM	Poseida Therapeutics, Inc. (PSTX) Is a Great Choice for 'Trend' Investors, Here's Why (Zacks)
Dec-11-22 10:30AM	Poseida Therapeutics Presents Preclinical Data from P-FVIII-101 Gene Therapy for Hemophilia A at the 64th ASH Annual Meeting & Exposition (PR Newswire)
Dec-06-22 09:55AM	Wall Street Analysts See an 189% Upside in Poseida Therapeutics, Inc. (PSTX): Can the Stock Really Move This High? (Zacks) -5.29%
06:00AM	Poseida Therapeutics to Present Early Data from Phase 1 Trials of P-MUC1C-ALLO1 and P-BCMA-ALLO1 at ESMO Immuno-Oncology 2022 Annual Congress (PR Newswire)
Nov-10-22 06:45PM	Poseida Therapeutics, Inc. (PSTX) Tops Q3 Earnings and Revenue Estimates (Zacks) +5.78%
04:05PM	Poseida Therapeutics Provides Updates and Financial Results for the Third Quarter of 2022 (PR Newswire)
Nov-08-22 08:00AM	Poseida Therapeutics to Present at Two Upcoming Investor Conferences (PR Newswire)
Nov-03-22 09:00AM	Poseida Therapeutics to Present at the ESMO Immuno-Oncology 2022 Annual Congress (PR Newswire) +6.28%
09:00AM	Poseida Therapeutics Announces Oral Presentation Highlighting P-FVIII-101 Gene Therapy at the 64th ASH Annual Meeting & Exposition (PR Newswire)
Oct-25-22 06:11AM	Both individual investors who control a good portion of Poseida Therapeutics, Inc. (NASDAQ:PSTX) along with institutions must be dismayed after last week's 15% decrease (Simply Wall St.) +6.25%
Oct-05-22 08:09AM	Poseida Therapeutics to Present Trial in Progress Poster for Phase 1 P-MUC1C-ALLO1 Study at the Society for Immunotherapy of Cancer Annual Meeting (PR Newswire) +6.29%
Sep-14-22 06:57AM	Investors in Poseida Therapeutics (NASDAQ:PSTX) have unfortunately lost 58% over the last year (Simply Wall St.)
Sep-07-22 04:05PM	Poseida Therapeutics to Present at H.C. Wainwright 24th Annual Global Investment Conference (PR Newswire) +10.62%
Aug-11-22 04:05PM	Poseida Therapeutics Provides Updates and Financial Results for the Second Quarter of 2022 (PR Newswire) +10.19% +7.06%
Aug-08-22 04:05PM	Poseida Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares (PR Newswire) -9.98%
Aug-04-22 08:00AM	Poseida Therapeutics Announces Pricing of Public Offering of Common Stock (PR Newswire)
07:00AM	Poseida Therapeutics Announces Proposed Public Offering of Common Stock (PR Newswire)

Poseida Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of non-viral gene engineering technologies for the treatment of hematological malignancies and solid tumors. Its products pipeline include autologous and allogeneic chimeric antigen receptor T cell, or CAR-T. The company was founded by Eric M. Ostertag in December 2014 and is headquartered in San Diego, CA.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

PSTX

Poseida Therapeutics Inc

Upgrade your FINVIZ experience